N
PEAR

Nuveen’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Nuveen’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-112,135
Closed -$132K – 3155
2022
Q4 		$132K Buy
112,135
+15,904
+17% +$33.4K ﹤0.01% 3086
2022
Q3 		$196K Buy
+96,231
New +$163K ﹤0.01% 3113

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nuveen's PEAR Position: Q1 2023 in Review

Nuveen sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q1 2023, closing a stake of 112,135 shares — an estimated $132K sold.

Nuveen first reported a position in PEAR in Q3 2022 and held it in 2 quarters. The position peaked at $196K in Q3 2022. 53 funds tracked by Wall St. Rank hold PEAR as of Q1 2023.

  • Nuveen reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Nuveen sold 112,135 Pear Therapeutics, Inc. Class A Common Stock shares in Q1 2023, an estimated $132K.
  • Nuveen first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 2 quarters.
  • Nuveen's Pear Therapeutics, Inc. Class A Common Stock position peaked at $196K in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q1 2023.

Based on Nuveen's 13F filing for Q1 2023, filed 15 May 2023.